Provider review
NativeMed review
Every product carries a struck-through price, permanently.
Reviewed by Lena OrtizMetabolic Health Editor
Price updated August 2026
We may earn a commission at no extra cost to you. Affiliate partners are listed first on our rankings. How we’re funded.
$149/mo sema · $183/mo tirz, both permanently marked down
Visit NativeMedWhat it actually charges is competitive — near the bottom of the field on semaglutide. What it displays beside those figures is a saving that was never available.
Price as published
NativeMed
$149/mo sema · $183/mo tirz, both permanently marked down
- Vs median
- $26/mo below the $175 median
- Market
- $59–$1,300/mo across 299 of 548
- Structure
- Standard plan, self-directed low dose
- Dispensed
- Pharmacy not publicly identified
Advertising disclosure · we may earn a commission if you start care through some of these links, at no extra cost to you.
In one paragraph
The verdict
Judged on what a reader would actually pay, this is priced well: the semaglutide figure sits near the bottom of the published range on this site and the tirzepatide one is competitive too. Judged on how those figures are presented, it is the pattern this site keeps having to point out. Every product carries a struck-through higher price beside the one being charged — on every item, with no end date published anywhere. A discount that never lifts is not a discount; it is the price with a larger number printed next to it to make the decision feel urgent, and the saving being advertised was never available to lose in the first place. The practical advice is simply to ignore the crossed-out figure entirely and compare the real one, which stands up perfectly well on its own and does not need the theater around it. Beyond that the gaps are the ordinary ones for this category: no dose behind either GLP-1 price, so what happens as the dose climbs is unstated, and no compounding pharmacy named anywhere.
Microdosing is off-label and unproven — decide with a clinician. Prices are as published by the provider when we last checked; confirm current terms before you buy.
Who it suits, and who it does not
A good fit if
- You are shopping the low end — the charged figures are genuinely competitive.
- You want both molecules priced openly before any intake.
- You want a provider that states plainly no insurance is needed.
Look elsewhere if
- You read a struck-through price as a saving. Every product here carries one.
- You want to know when a sale ends. No end date is published for any of them.
- You are pricing a dose. None is published behind either figure.
What it actually costs
Price as published
$149/mo sema · $183/mo tirz, both permanently marked down
- Vs median
- $26/mo below the $175 median across the 299 of 548 programs here that publish a plain monthly rate
- Market
- $59–$1,300/mo is the full published spread on this site
- Structure
- Standard plan, self-directed low dose
No low-dose product of its own. Starting low means asking for a smaller amount inside a standard plan, at the standard plan's price.
235 of the 548 programs here price a small dose this way. Both molecules carry a real charged price readable before intake, and both sit at the low end. Each is displayed beside a permanently struck-through higher figure with no end date, so the advertised saving is decoration rather than a saving. No low-dose product is offered.
Microdosing is off-label and unproven — decide with a clinician. Prices are as published by the provider when we last checked; confirm current terms before you buy.
What is included
- Consult
- Included in the price
- Dietitian
- Not confirmed
- Labs
- Not required
- Pricing
- Check plan terms
What it does well
- The prices actually charged sit at the low end of the published field.
- Both molecules are priced openly before any intake, alongside a NAD+ line.
- States plainly that no insurance is needed.
Pharmacy, labs and oversight
NativeMed does not publicly identify the pharmacy that fills its prescriptions. No bloodwork is required before you start. A clinician review is included in the price.
Transparency check
2 of 4 published openly
What NativeMed publishes about itself, read from its own pages when we verified them — not estimated, and not a score.
- Pharmacy named and regulatedNo pharmacy is identified anywhere on its own pages.
- Not published
- A price you can read before intakeA monthly rate is published on its own pages — the figure in the price row above, read there and verified against it.
- Published
- What a higher dose costsPriced by dose, plan or tier, and the higher rungs are not published — the advertised figure does not tell you what a larger dose costs.
- Not published
- No FDA warning letter on fileChecked against the FDA's own warning-letter database; nothing on file for this company.
- None on file
How the program works
Judged on what a reader would actually pay, this is priced well — the semaglutide figure sits near the bottom of the published range and the tirzepatide one is competitive too. Judged on how those figures are presented, it is the pattern this site keeps having to point out. Every product carries a struck-through higher price beside the one being charged, on every item, with no end date published anywhere. A discount that never lifts is not a discount; it is the price with a larger number printed next to it to make the decision feel urgent, and the saving it advertises was never available to lose. The practical advice is simply to ignore the crossed-out figure entirely and compare the real one, which stands up perfectly well on its own and does not need the theater. Beyond that the gaps are the usual ones: no dose behind either GLP-1 price, so what happens as the dose climbs is unstated, and no compounding pharmacy named.
The honest cons
Every product carries a permanent struck-through price, so the advertised saving is not one.
- No end date is published for any sale, which is what makes it permanent.
- No dose is published behind either figure and no pharmacy is named.
Microdosing is off-label and unproven — decide with a clinician. Prices are as published by the provider when we last checked; confirm current terms before you buy.
How it compares
NativeMed is one of 548 low-dose GLP-1 programs compared on this site, and 299 of them publish a monthly rate you can read before signing up. The full list puts every published price in one place, with the companies that pay us listed first — something we state there, on the page it applies to.
Also consider
Two more programs that price a small dose the way NativeMed does. Both are partners: we may earn a commission if you start care through these links.
Partner
RxSpan MD
$249/mo month to month ($199 on 6-mo)
Standard plan, self-directed low dose
Partner
HealthRX
$190/mo sema · $239/mo tirz (monthly plan)
Standard plan, self-directed low dose
Where this sits
#218 of 548
Ordered with the companies that pay us first, and NativeMed is not one of them. A disclosed partition, not a score.
Compare all 548 providers →Read this before you buy
Intentional GLP-1 microdosing is off-label and unproven — no randomized trial has established that a sub-label dose does anything, and any dose belongs with a clinician who knows your history. If you are going to have that conversation, have it with real numbers.
- What microdosing GLP-1 costs
- What the evidence actually shows
- The true annual cost of a plan
- What a flat price costs at a low dose
Microdosing is off-label and unproven — decide with a clinician. Prices are as published by the provider when we last checked; confirm current terms before you buy.
The closest alternative
Peter MD
$149/mo GLP1+B12 · $249/mo tirz (quarterly)
- Vs median
- $26/mo below the $175 median
- Market
- $59–$1,300/mo across 299 of 548
- Structure
- Standard plan, self-directed low dose
- Dispensed
- Pharmacy not publicly identified
Advertising disclosure · we may earn a commission if you start care through some of these links, at no extra cost to you.
Read the Peter MD review →Microdosing is off-label and unproven — decide with a clinician. Prices are as published by the provider when we last checked; confirm current terms before you buy.